Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children

被引:1
|
作者
Satirer, Oezlem [1 ,2 ]
Henes, Joerg C. [3 ,4 ]
Doering, Michaela [5 ]
Lesk, Till [6 ]
Benseler, Susanne [7 ,8 ]
Kuemmerle-Deschner, Jasmin Beate [1 ,2 ]
机构
[1] Univ Klinikum Tubingen, Dept Paediat, Tubingen, Baden Wurttembe, Germany
[2] Univ Klinikum Tubingen, Autoinflammat Reference Ctr Tuebingen arcT, Tubingen, Baden Wurttembe, Germany
[3] Univ Klinikum Tubingen, Ctr Interdisciplinary Clin Immunol Rheumatol & Aut, Tubingen, Baden Wurttembe, Germany
[4] Univ Klinikum Tubingen, Dept Internal Med Oncol Haematol Immunol & Rheumat, Tubingen, Baden Wurttembe, Germany
[5] Univ Tubingen, Pediat Hematol & Oncol, Tubingen, Baden Wurttembe, Germany
[6] Univ Klinikum Tubingen, Tubingen, Baden Wurttembe, Germany
[7] Alberta Childrens Hosp Res Inst, Rheumatol, Calgary, AB, Canada
[8] Childrens Hlth Ireland, Dublin, Ireland
来源
RMD OPEN | 2024年 / 10卷 / 03期
关键词
Treatment; Autoimmune Diseases; Hematopoietic Stem Cell Transplantation; JUVENILE IDIOPATHIC ARTHRITIS; CAR T-CELLS; SYSTEMIC-SCLEROSIS; ACTIVITY CRITERIA; INTERNATIONAL CONSENSUS; ETANERCEPT; GUIDELINES; BLOOD; IMMUNOTHERAPY; MULTICENTER;
D O I
10.1136/rmdopen-2024-004381
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate the long-term effectiveness and safety of autologous haematopoiesis stem cell transplantation (AHSCT) for severe, refractory autoimmune diseases in paediatric patients.Methods A single-centre study of consecutive children and adolescents with refractory autoimmune diseases undergoing AHSCT was performed. Demographics, clinical, laboratory features, pre-AHSCT medications, disease activity and functional status were captured. The primary outcome was progression-free survival, secondary outcomes included overall survival, disease-specific treatment responses, disease activity at the last follow-up and AHSCT safety.Results The study included seven patients: two systemic sclerosis, one pansclerotic morphoea, one eosinophilic fasciitis, one juvenile dermatomyositis and two patients with systemic juvenile idiopathic arthritis; four women, three men median age at AHSCT of 10 years (7-19), median follow-up post-AHSCT of 17 years. Median progression-free survival and overall survival was 4.2 years (95% CI: 0.98 to 8.3) and 17 years (95% CI: 11.8 to 22.1), respectively. Progression-free survival rates at 1 and 2 years post-AHSCT were 100% and 77%, respectively. All children survived. All patients are in clinical remission, only four require ongoing immunotherapy. Safety: Three experienced infections, including HHV6, Candida and Ralstonia sepsis; one developed a systemic inflammatory response syndrome; two new onset secondary autoimmune diseases including autoimmune haemolytic anaemia, Graves' disease and one was found to have a breast fibroadenoma. Treatment toxicity: one cyclophosphamide-associated transient renal failure and pericardial effusion, one patient with amenorrhoea/infertility.Conclusions AHSCT was an effective and safe approach for children and adolescents with treatment-refractory autoimmune diseases. The indication and timing of transplantation requires a careful consideration and a multidisciplinary approach.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [1] Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - a guide for the generalist
    Snowden, John A.
    Sharrack, Basil
    Akil, Mohammed
    Kiely, David G.
    Lobo, Alan
    Kazmi, Majid
    Muraro, Paolo A.
    Lindsay, James
    CLINICAL MEDICINE, 2018, 18 (04) : 329 - 334
  • [2] Autologous haemopoietic stem cell transplantation for autoimmune diseases
    Zeher, Margit
    Papp, Gabor
    Szodoray, Peter
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (09) : 1193 - 1201
  • [3] Autologous hematopoietic stem cell transplantation in autoimmune diseases
    Annaloro, Claudio
    Onida, Francesco
    Deliliers, Giorgio Lambertenghi
    EXPERT REVIEW OF HEMATOLOGY, 2009, 2 (06) : 699 - 715
  • [4] Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: From Mechanistic Insights to Biomarkers
    Ribeiro Malmegrim, Kelen Cristina
    Lima-Junior, Joao Rodrigues
    Marliere Arruda, Lucas Coelho
    Cottas de Azevedo, Julia Teixeira
    Vilela de Oliveira, Gislane Lelis
    Oliveira, Maria Carolina
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [5] Autologous hemopoietic stem-cell transplantation for children with refractory autoimmune disease
    Wulffraat N.M.
    Sanders L.A.
    Kuis W.
    Current Rheumatology Reports, 2000, 2 (4) : 316 - 323
  • [6] Hematopoietic Stem Cell Transplantation in Children with Autoimmune Connective Tissue Diseases
    Witkowska, Magdalena
    Smolewska, Elzbieta
    Smolewski, Piotr
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2014, 62 (04) : 319 - 327
  • [7] Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases
    Daikeler, Thomas
    Tichelli, Andre
    Passweg, Jakob
    PEDIATRIC RESEARCH, 2012, 71 (04) : 439 - 444
  • [8] Haematopoietic stem cell transplantation in the treatment of autoimmune diseases
    Mahevas, M.
    Vaida, I.
    Le Page, L.
    Sid-Idris, S.
    Royer, B.
    Garedi, R.
    Damaj, G.
    Duhaut, P.
    Claisse, J. -F
    Ducroix, J. -P.
    Marolleau, J. -P.
    REVUE DE MEDECINE INTERNE, 2008, 29 (02): : 115 - 121
  • [9] Application of stem cell transplantation in autoimmune diseases
    Ng, Sue-Ann
    Sullivan, Keith M.
    CURRENT OPINION IN HEMATOLOGY, 2019, 26 (06) : 392 - 398
  • [10] Cellular therapy for autoimmune diseases: Beyond autologous hematopoietic stem cell transplantation
    Maria, A. T. J.
    REVUE DE MEDECINE INTERNE, 2023, 44 (05): : A35 - A40